Clinical momentum Zetagen is a private, clinical-stage biopharmaceutical company focused on intratumoral therapies for metastatic and primary breast cancer, with Phase 2a results and multiple FDA Breakthrough Designations that can help accelerate conversations with oncology researchers, hospital systems, and payer decision-makers seeking innovative bone and liver metastasis treatments.

Strategic partnerships The company has secured NIH/NCI grants and undergone Series A and B financing, signaling strong investor confidence and potential co-development opportunities with academic centers, contract research organizations, and large pharma partners interested in early-stage, tumor-localized therapeutics.

Intellectual property A robust IP portfolio with over 70 issued patents including Composition-of-Matter rights creates defensible technology for collaboration talks, licensing deals, and joint ventures around ZetaMet, ZetaMast, and ZetaPrime platforms.

Specialized patient access Intratumoral delivery with localized action positions Zetagen to target high-need breast cancer patient segments definitively, opening conversations with oncology centers, bone metastasis clinics, and liver metastasis programs about trials, compassionate use, and early-access pathways.

Growth indicators Recent financing milestones including a $12.9M Series B1 and ongoing activity at major conferences (SABCS, ASCO) signal momentum and a receptive market for new treatment modalities, providing opportunities to engage potential pharma licensing partners, distributors, and strategic advisors.